Question 17 of 20 Advanced Scenario
What would you do when the data support a narrower indication than the commercial team wants?
Short answer
Show the commercial team exactly which population the evidence supports and why, using the trial's eligibility, the primary analysis and subgroup credibility. Propose the indication the data can defend, explain the cost of a refused or delayed application, and outline the evidence that could widen the label later.
Why
An indication must match the population studied and the effect shown. If a trial enrolled adults with moderate to severe disease after one prior therapy, a broad 'all adults' claim asks the regulator to extrapolate. Regulators will usually narrow the label themselves, but an overreaching application can cost review time, raise credibility questions and in some cases lead to refusal.
EMA's subgroup guideline explains that subgroup results need pre-specification, biological plausibility and replication to be credible. So a strong benefit in an unplanned subgroup rarely supports a separate claim, and a weak effect in part of the trial population may justify excluding it. The regulatory professional's job is to make the trade-off visible: the narrow label is likely approved on time, the broad label may be delayed or narrowed anyway.
Offer a path, such as a post-approval trial in the wider population, a label update supported by real world data, or a paediatric plan. Then document the decision so the company owns it with full information.
A strong answer covers
- Indication must match studied population and shown effect
- Subgroup credibility criteria
- Cost of overreaching: delay, credibility, refusal
- Path to a broader label later
- Documented, informed company decision
Common mistakes
- Submitting the broad indication and hoping the regulator agrees.
- Refusing to engage with commercial goals instead of offering options.
- Using an unplanned subgroup to justify a claim.
The interviewer might ask next
What evidence would you plan to support expanding the indication after approval?